On 13th March, UK Prime Minister Sir Keir Starmer announced the abolition of NHS England (NHSE) to “cut bureaucracy” and bring management of the health service “back into democratic control”. The day before, Sir Jim Mackey, interim CEO of NHSE, announced a significant restructuring of ICBs, mandating a 50% reduction in their costs. This will lead to the merger of several ICBs and a substantial reduction in leadership roles. The restructuring is expected to have significant repercussions for the Pharmaceutical and Medtech industries. Learn more about the announcement and our initial thoughts on the implications for industry here. In response, we are hosting a series of NHS Whispers specials to gain early perspectives and direct insights on what this means for the NHS and industry, from those responding to these changes and driving decision-making in the NHS.
This first session will be conducted live under ‘Chatham House Rules’, to enable our speakers to share their views openly in these changing times and facilitate a live, active discussion. We will be taking questions directly from you in the session. You can also submit questions in advance when you register. To enable this active discussion, the webinar will not be recorded, so please attend live with your questions!
What questions will you put forward? The session will be shaped by the questions we receive in advance and on the day, by the live audience. We anticipate, this could include:
- How will the abolition of NHSE affect market access in England?
- What does the restructuring on ICBs mean for Pharma market access?
- How quickly can we expect to see changes on the ground?
- What will this mean for the future of ICBs?
- What will this mean for specialised commissioning and the devolution of specialised services to ICBs?
- Where and how will this change decision-making?
- How should Pharma and Medtech be adapting their strategies?
Please register and add your question to the list.